Up-regulation of NFκB-responsive gene expression by ΔNp73α in p53 null cells

Experimental Cell Research

Volumn 312, Issue 8, 2006, Pages 1254-1264

  Tanaka, Yasuharu ^a   Ota, Katsuya ^a   Kameoka, Masanori ^a   Itaya, Asako ^a   Yoshihara, Koichiro ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

DeltaNp73; H1299; NF B; p53; p73; Saos 2; TAp73; Tp73; Np73; TAp73

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOPROTEIN; LUCIFERASE; P 73 PROTEIN; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PEPTIDE FRAGMENT; PROTEIN BCL X; TP73 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENHANCER REGION; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NULL CELL; PLASMID; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN VARIANT; REPORTER GENE; TRANSACTIVATION; UPREGULATION; ACTIVE TRANSPORT; CELL TRANSFORMATION; GENETICS; HELA CELL; METABOLISM; MUTATION; NEOPLASM; PROTEIN TERTIARY STRUCTURE; REGULATORY SEQUENCE; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; BCL-X PROTEIN; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HELA CELLS; HUMANS; MUTATION; NEOPLASMS; NF-KAPPA B; NUCLEAR PROTEINS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; REGULATORY ELEMENTS, TRANSCRIPTIONAL; TRANS-ACTIVATION (GENETICS); TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 33646071842     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2005.12.013     Document Type: Article

References (58)

1. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.-C., Valent A., Minty A., Chalon P., Lelias J.-M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
2. de Laurenzi V., Constanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., Levrero M., and Melino G. Two new splice variants, γ and δ, with different transcriptional activity. J. Exp. Med. 188 (1998) 1763-1768
3. Zaika A.I., Kovalev S., Marchenko N.D., and Moll U.M. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59 (1999) 3257-3263
4. de Laurenzi V., Catani M.V., Terrinoni A., Corazzari M., Melino G., Costanzo A., Levrero M., and Knight R.A. Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ. Cell Death Differ. 6 (1999) 389-390
5. Ueda Y., Hijikata M., Takagi S., Chiba T., and Shimotohno K. New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 18 (1999) 4993-4998
6. Bénard J., Douc-Rasy S., and Ahomadegbe J.-C. TP53 family members and human cancers. Hum. Mutat. 21 (2003) 182-191
7. Chen X. The p53 family: same response, different signals?. Mol. Med. Today 5 (1999) 387-392
8. Fontemaggi G., Kelar I., Amariglio N., Rechavi G., Krishnamurthy J., Strano S., Sacchi A., Givol D., and Blandino G. Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J. Biol. Chem. 277 (2002) 43359-43368
9. Harms K., Nozell S., and Chen X. The common and distinct target genes of the p53 family transcription factors. Cell. Mol. Life Sci. 61 (2004) 822-842
10. Pozniak C.D., Radinovic S., Yang A., McKeon F., Kaplan D.R., and Miller F.D. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289 (2000) 304-306
11. Pozniak C.D., Barnabé-Heider F., Rymer V.V., Lee A.F., Sadikot A.F., and Miller F.D. p73 is required for survival and maintenance of CNS neurons. J. Neurosci. 22 (2002) 9800-9809
12. Sayan A.E., Sayan B.S., Findikli N., and Ozturk M. Acquired expression of transcriptionally active p73 in hepatocellular carcinoma cells. Oncogene 20 (2001) 5111-5117
13. Ishimoto O., Kawahara C., Enjo K., Obinata M., Nukiwa T., and Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 62 (2002) 636-641
14. Grob T.J., Novak U., Maisse C., Barcaroli D., Lüthi A.U., Pirnia F., Hügli B., Graber H.U., de Laurenzi V., Fey M.F., Melino G., and Tobler A. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 8 (2001) 1213-1223
15. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
16. Nakagawa T., Takahashi M., Ozaki T., Watanabe K., Todo S., Mizuguchi H., Hayakawa T., and Nakagawara A. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol. Cell. Biol. 22 (2002) 2575-2585
17. Kartasheva N.N., Contente A., Lenz-Stöppler C., Roth J., and Dobbelstein M. p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop. Oncogene 21 (2002) 4715-4727
18. Stiewe T., Theseling C.C., and Pützer B.M. Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding. J. Biol. Chem. 277 (2002) 14177-14185
19. Kartasheva N.N., Lenz-Bauer C., Hartmann O., Schäfer H., Eilers M., and Dobbelstein M. ΔNp73 can modulate the expression of various genes in a p53-independent fashion. Oncogene 22 (2003) 8246-8254
20. Tanaka Y., Kameoka M., Itaya A., Ota K., and Yoshihara K. Regulation of HSF1-responsive gene expression by N-terminal truncated form of p73α. Biochem. Biophys. Res. Commun. 317 (2004) 865-872
21. Liu G., Nozell S., Xiao H., and Chen X. ΔNp73β is active in transactivation and growth suppression Mol. Cell Biol. 24 (2004) 487-501
22. Lee A.F., Ho D.K., Zanassi P., Walsh G.S., Kaplan D.R., and Miller F.D. Evidence that ΔNp73 promotes neuronal survival by p53-dependent and p53-independent mechanisms. J. Neurosci. 24 (2004) 9174-9184
23. Kumar A., Takada Y., Boriek A.M., and Aggarwal B.B. Nuclear factor-κB: its role in health and disease. J. Mol. Med. 82 (2004) 434-448
24. Pahl H.L. Activators and target genes of Rel/NFκB transcription factors. Oncogene 18 (1999) 6853-6866
25. Ravi R., Mookererjee B., van Hensbergen Y., Bedi G.C., Giordano A., El-Deiry W.S., Fuchs E.J., and Bedi A. p53-mediated repression of nuclear factor-κB RelA via the transcriptional integrator p300. Cancer Res. 58 (1999) 4531-4536
26. Wadgaonkar R., Phelps K.M., Haque Z., Williams A.J., Silverman E.S., and Collins T. CREB-binding protein is a nuclear integrator of nuclear factor-κB and p53 signaling. J. Biol. Chem. 274 (1999) 1879-1882
27. Webster G.A., and Perkins N.D. Transcriptional cross talk between NF-κB and p53. Mol. Cell. Biol. 19 (1999) 3485-3495
28. Ikeda A., Sun X., Li Y., Zhang Y., Eckner R., Doi T.S., Takahashi T., Obata Y., Yoshioka K., and Yamamoto K. p300/CBP-dependent and -independent transcriptional interference between NF-κB RelA and p53. Biochem. Biophys. Res. Commun. 272 (2000) 375-379
29. Shao J., Fujiwara T., Kadowaki Y., Fukazawa T., Waku T., Itoshima T., Yamatsuji T., Nishizaki M., Roth J., and Tanaka N. Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19 (2000) 726-736
30. Culmsee C., Siewe J., Junker V., Retiounskaia M., Schwarz S., Camandola S., El-Metainy S., Behnke H., Mattson M.P., and Krieglstein J. Reciprocal inhibition of p53 and nuclear factor-κB transcriptional activities determined cell survival or death in neurons. J. Neurosci. 23 (2003) 8586-8595
31. E.A. Komarova, V. Krivokrysenko, K. Wang, N. Neznanov, M.V. Chernov, P.G. Komarov, M.-L. Brennan, T.V. Golovkina, O. Rokhlin, D.V. Kuprash, S.A. Nedospasov, S.R. Hazen, E. Feinstein, A.V. Gudkov, p53 is a suppressor of inflammatory response in mice, FASEB J. (2005). doi:10.1096/fj.04-3213.
32. Pierce J.W., Schoenleber R., Jesmok G., Best J., Moore S.A., Collins T., and Gerritsen M.E. Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 272 (1997) 21096-21103
33. Hayakawa M., Miyashita H., Sakamoto I., Kitagawa M., Tanaka H., Yasuda H., Karin M., and Kikugawa K. Evidence that reactive oxygen species do not mediate NF-κB activation. EMBO J. 22 (2003) 3356-3366
34. Nurmi A., Vartiainen N., Pihlaja R., Goldsteins G., Yrjänheikki J., and Koistinaho J. Pyrrolidine dithiocarbamate inhibits translocation of nuclear factor kappa-B in neurons and protects against brain ischaemia with a wide therapeutic time window. J. Neurochem. 91 (2004) 755-765
35. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 4844-4849
36. Rossi A., Kapahi P., Natoli G., Takahashi T., Chen Y., Karin M., and Santoro M.G. Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I(B kinase. Nature 403 (2000) 103-108
37. 2 in activated murine macrophages. Mol. Cell. Biol. 20 (2000) 1692-1698
38. Tanaka Y., Kameoka M., Ota K., Itaya A., Ikuta K., and Yoshihara K. Establishment of persistent infection with HIV-1 abrogates the caspase-3-dependent apoptotic signaling pathway in U937 cells. Exp. Cell Res. 247 (1999) 514-524
39. Mitsudomi T., Steinberg S.M., Nau M.M., Carbone D., D'Amico D., Bodner S., Oie H.K., Linnoila R.I., Mulshine J.L., Minna J.D., and Gazadar A.F. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7 (1992) 171-180
40. Aurelio O.N., Kong X., Guputa S., and Stanbridge E.J. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol. 20 (2000) 770-778
41. Chen P.-L., Chen Y., Bookstein R., and Lee W.-H. Genetic mechanisms of tumor suppression by the human p53 genes. Science 250 (1990) 1576-1580
42. Yuan Z.-M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y.Y., Lu H., Kharbanda S., Weichselbaum R., and Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399 (1999) 814-817
43. 2/M transition. J. Biol. Chem. 278 (2003) 49196-49202
44. Chi S.-W., Ayed A., and Arrowsmith C.H. Solution structure of a conserved C-terminal domain of p73 with structural homology to the SAM domain. EMBO J. 18 (1999) 4438-4445
45. Thanos C.D., and Bowie J.U. p53 family members p63 and p73 are SAM domain-containing proteins. Protein Sci. 8 (1999) 1708-1710
46. Ozaki T., Naka M., Takada N., Tada M., Sakiyama S., and Nakagawara A. Deletion of the COOH-terminal region of p73α enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res. 59 (1999) 5902-5907
47. Munarrz E., Barcaroli D., Stephanou A., Townsend P.A., Maisse C., Terrinoni A., Neale M.H., Martin S.J., Latchman D.S., Knight R.A., Melino G., and De Laurenzi V. PIAS-1 is a checkpoint regulator which affects exit from G1 and G2 by sumoylation of p73. Mol. Cell. Biol. 24 (2004) 10593-10610
48. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., Chalas E., and Moll U.M. ΔNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196 (2002) 765-780
49. Stiewe T., Zimmermann S., Frilling A., Esche H., and Pützer B.M. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 62 (2002) 3598-3602
50. Casciano I., Mazzocco K., Boni L., Pagnan G., Banelli B., Allemanni G., Ponzoni M., Tonini G.P., and Romoni M. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9 (2002) 246-251
51. Douc-Rasy S., Barrois M., Echeynne M., Kaghad M., Blanc E., Raguenez G., Goldschneider D., Terrier-Lacombe M., Hartmann O., Moll U., Caput D., and Bénard J. ΔNp73α accumulates in human neuroblastic tumors. Am. J. Pathol. 160 (2002) 631-639
52. Pützer B.M., Tube S., Tannapfel A., and Stiewe T. Increased ΔN-p73 expression in tumors by upregulation of the E2F1-regulated, TA-promoter-derived ΔN'-p73 transcript. Cell Death Differ. 10 (2002) 612-614
53. Concin N., Becker K., Slade N., Erster S., Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., and Moll U.T. Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64 (2004) 2449-2460
54. Uramoto H., Sugio K., Oyama T., Nakata S., Ono K., Morita M., Funa K., and Yasumoto K. Expression of ΔNp73 predicts poor prognosis in lung cancer. Clin. Cancer Res. 10 (2004) 6905-6911
55. Beere H.M., Wolf B.B., Cain K., Mosser D.D., Mahboubi A., Kuwata T., Tailor P., Morimoto R.I., Cohen G.M., and Green D.R. Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome. Nat. Cell Biol. 2 (2000) 469-475
56. Saleh A., Srinivasula S.M., Balkir L., Robbins P.D., and Alnemri E.S. Negative regulation of the Apaf-1 apoptosome by Hsp70. Nat. Cell Biol. 2 (2000) 476-483
57. Kucharczak J., Simmons M.J., Fan Y., and Gélinas C. To be, or not to be: NFκB is the answer - Role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22 (2003) 8961-8982
58. Ciien C., Edelstein L.C., and Gélinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-XL. Mol. Cell. Biol. 20 (2000) 2687-2695